




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 277/00		A2	(11) International Publication Number: WO 00/51993
			(43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/US00/05195 (22) International Filing Date: 1 March 2000 (01.03.00) (30) Priority Data: 60/122,718 3 March 1999 (03.03.99) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors: CHENG, Menyan ; 5860 Hazeltine Court, West Chester, OH 45069 (US). ALMSTED, Neil, Gregory ; 6348 Trail Ridge Court, Loveland, OH 45140 (US). NATCHUS, Michael, George ; 1096 Laurel Avenue, Glen- dale, OH 45246 (US). PIKUL, Stanislaw ; 4640 Placepointe Drive, Mason, OH 45040 (US). DE, Biswanath ; 11269 Cornell Woods Drive, Cincinnati, OH 45241 (US). (74) Agents: REED, T., David et al. ; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS



(57) Abstract

Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to formula (I): where J, M, Q, T, W, X, Z, R¹, R², R³, R⁴, R⁵, R⁶, R^{6'}, R⁷, m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.